story of the week
Efficacy of Ribociclib Plus Endocrine Therapy vs Combination Chemotherapy in Premenopausal Women With Clinically Aggressive HR+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer
J. Clin. Oncol 2024 May 21;[EPub Ahead of Print], YS Lu, EI Bin Mohd Mahidin, H Azim, Y Eralp, YS Yap, SA Im, J Rihani, E Gokmen, A El Bastawisy, N Karadurmus, YN Lim, CS Lim, LT Duc, WP Chung, KG Babu, K Penkov, J Bowles, TD Alfaro, J Wu, M Gao, K Slimane, NS El SaghirFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.